Neurodegeneration No More: Cutting-Edge Technologies and Therapies in the Evolution of Neurodegenerative Disease Management

A topical collection in Biomedicines (ISSN 2227-9059). This collection belongs to the section "Neurobiology and Clinical Neuroscience".

Viewed by 1822


E-Mail Website
Collection Editor
HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged (HUN-REN-SZTE), Szeged, Hungary
Interests: neurohormones; neuropeptides; tryptophan; kynurenine; psychiatry; neurology; depression; anxiety; dementia; pain; Alzheimer’s disease; cognition; antidepressant; translational research
Special Issues, Collections and Topics in MDPI journals

E-Mail Website1 Website2
Collection Editor
1. Department of Psychology, University of Turin, Turin, Italy
2. Center for Studies and Research in Cognitive Neuroscience, Department of Psychology, University of Bologna, Bologna, Italy
Interests: NIBS techniques; TMS; skin conductance; heart rate variability; fear conditioning; fear learning; learning; neuropsychology; prefrontal cortex; amygdala; hippocampus; anxiety; depression; working memory; PTSD; skin conductance responses; psychophysiology; error-related negativity; EEG; tDCS; Alzheimer’s disease; PIT; stress-related disorders; Parkinson’s disease; resilience; memory; neurologic patients; cognitive decisions; fMRI; translational and molecular psychiatry
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Collection Editor
Department of Psychology, University of Turin, Turin, Italy
Interests: magnetic resonance imaging; human brain mapping; meta-research; connectomics; brain connectivity; computational neuroscience; Bayesian statistics; fMRI; meta-analysis; clinical trials; DTI; default mode network; Alzheimer’s disease; biological psychiatry; autism; cerebellum; translational neuroimaging

Topical Collection Information

Dear Colleagues,

Neurodegenerative diseases are a group of disorders that affect the structure and function of the central nervous system, leading to the progressive loss of cognitive, motor, and sensory abilities. They include Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and many others. Neurodegenerative diseases pose a major challenge for public health as they affect millions of people worldwide and have no cure. Moreover, they are associated with a high burden of disability, morbidity, mortality, and socioeconomic costs.

In recent years, significant advances have been made in the understanding of the pathophysiology, epidemiology, and genetics of neurodegenerative diseases, as well as in the development of novel diagnostic tools, therapeutic interventions, and rehabilitation strategies. Non-invasive brain stimulation (NIBS) techniques, such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), have shown potential to improve both motor and nonmotor symptoms in patients with neurodegenerative diseases like Alzheimer’s and Parkinson’s. These techniques are of particular interest for the treatment of cognitive impairment in Alzheimer’s disease and axial disturbances in Parkinson’s disease, where conventional pharmacological therapies have shown limited effects. Recent evidence suggests that NIBS may have a neuroprotective effect, potentially slowing disease progression and modulating the aggregation state of pathological proteins. However, many gaps and challenges remain in the field, such as the identification of reliable biomarkers, the elucidation of the environmental and lifestyle factors that modulate disease risk and progression, the optimization of clinical trials and drug delivery systems, and improvements in the quality of life and care of patients and caregivers. Moreover, the potential of NIBS to influence disease progression over time remains poorly understood, along with ongoing investigations into the development of standardized stimulation protocols for the precise targeting of deep brain regions.

This Topical Collection aims to showcase the latest research and innovations in the field of neurodegenerative diseases, covering a wide range of topics, such as the following:

  • Risk factors, such as genetic and environmental, that influence the onset and course of neurodegenerative diseases;
  • Prodromal symptoms and early diagnosis, using advanced imaging techniques, biomarkers, and digital technologies;
  • Comorbidities, such as psychiatric, metabolic, and cardiovascular disorders, that affect or are affected by neurodegenerative diseases;
  • Novel therapeutic targets and treatments, such as gene therapy, stem cell therapy, immunotherapy, medicinal plants, phytocompounds, and neuroprotective agents;
  • Role of oxidative stress and inflammation as triggers of neurodegenerative conditions;
  • Quality-of-life-oriented rehabilitation, such as cognitive, physical, and psychosocial interventions that enhance the functioning and well-being of patients and caregivers;
  • Innovative translational research, such as bench-to-bed and bed-to-bench, and modeling, such as in vitro and in vivo;
  • Non-invasive brain stimulation (NIBS) as a therapeutic intervention that may offer neuroprotective effects and improve symptoms in neurodegenerative diseases.

We invite researchers and clinicians from various disciplines and backgrounds to submit their original articles and reviews to this Topical Collection contribute to the advancement of knowledge and practice in the field of neurodegenerative diseases. We hope that this Topical Collection will provide a comprehensive and up-to-date overview of the current state and future directions of the field and will stimulate further research and collaboration among the scientific community.

Dr. Masaru Tanaka
Dr. Simone Battaglia
Dr. Donato Liloia
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Alzheimer’s disease
  • frontotemporal lobar degeneration
  • Parkinson’s disease
  • aging decline
  • mild cognitive impairment
  • multiple sclerosis
  • stroke
  • acquired brain damage
  • altered cognitive processes
  • brain functional impairment
  • neurocognitive disorders
  • cognitive, behavioral, and functional disorders
  • acquired trauma
  • brain plasticity and connectivity
  • non-invasive brain stimulation
  • diagnosis and treatment
  • functional evidence of altered cognition and connectivity
  • blood-based biomarkers
  • disease heterogeneity
  • prognosis
  • protein aggregation
  • inflammation
  • oxidative stress
  • medicinal plants
  • phytocompounds

Published Papers (1 paper)


17 pages, 3161 KiB  
Comparison of Protective Effects of Antidepressants Mediated by Serotonin Receptor in Aβ-Oligomer-Induced Neurotoxicity
by Ken Yamamoto, Mayumi Tsuji, Tatsunori Oguchi, Yutaro Momma, Hideaki Ohashi, Naohito Ito, Tetsuhito Nohara, Tatsuya Nakanishi, Atsushi Ishida, Masahiro Hosonuma, Toru Nishikawa, Hidetomo Murakami and Yuji Kiuchi
Biomedicines 2024, 12(6), 1158; - 23 May 2024
Viewed by 242
Amyloid β-peptide (Aβ) synthesis and deposition are the primary factors underlying the pathophysiology of Alzheimer’s disease (AD). Aβ oligomer (Aβo) exerts its neurotoxic effects by inducing oxidative stress and lesions by adhering to cellular membranes. Though several antidepressants have been investigated as neuroprotective [...] Read more.
Amyloid β-peptide (Aβ) synthesis and deposition are the primary factors underlying the pathophysiology of Alzheimer’s disease (AD). Aβ oligomer (Aβo) exerts its neurotoxic effects by inducing oxidative stress and lesions by adhering to cellular membranes. Though several antidepressants have been investigated as neuroprotective agents in AD, a detailed comparison of their neuroprotection against Aβo-induced neurotoxicity is lacking. Here, we aimed to elucidate the neuroprotective effects of clinically prescribed selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, and noradrenergic and specific serotonergic antidepressants at the cellular level and establish the underlying mechanisms for their potential clinical applications. Therefore, we compared the neuroprotective effects of three antidepressants, fluoxetine (Flx), duloxetine (Dlx), and mirtazapine (Mir), by their ability to prevent oxidative stress-induced cell damage, using SH-SY5Y cells, by evaluating cell viability, generation of reactive oxygen species (ROS) and mitochondrial ROS, and peroxidation of cell membrane phospholipids. These antidepressants exhibited potent antioxidant activity (Dlx > Mir > Flx) and improved cell viability. Furthermore, pretreatment with a 5-hydroxytryptamine 1A (5-HT1A) antagonist suppressed their effects, suggesting that the 5-HT1A receptor is involved in the antioxidant mechanism of the antidepressants’ neuroprotection. These findings suggest the beneficial effects of antidepressant treatment in AD through the prevention of Aβ-induced oxidative stress. Full article
Show Figures

Figure 1

Back to TopTop